Can Moderna Beat the Omicron Variant?
Moderna (NASDAQ: MRNA) has proved itself when it comes to handling the original coronavirus and the variants that have emerged since the beginning of the year. The biotech company's vaccine has offered protection across the board. In fact, some real-world studies have even shown Moderna's vaccine to be more efficacious than those of its rivals.
But things happen fast in the world of coronavirus prevention. And a new challenge is right here, right now. It's called the omicron variant. South Africa detected the first case of it in early November, and since, the variant has spread to Europe. Now, the big question is whether vaccine giant Moderna can beat this quickly spreading variant. The answer could be critical for Moderna -- and its share price. Let's take a look at where Moderna stands.
Image source: Getty Images.
Source Fool.com
